ATLANTA, GA--(Marketwire - January 09, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has restructured an additional $17.5 million of its remaining 2008 convertible debt. With the completion of this transaction, the Company’s original $100 million in face value of 2008 convertible notes has been reduced to $30.5 million. At December 31, 2007, the Company had approximately $93 million in cash and short term investments.
